- Lee Schwartzberg, MD, FACP, Chairman, President, and Chief Medical Officer
- Michael Choukas, Chief Executive Officer
- Edward Stepanski, PhD, Chief Operating Officer
- Sean Hart, EVP & Managing Director, Pharma Services
- Anne (Stratemeier) Werr, Executive Director, Finance
Lee Schwartzberg, MD, FACP, Chairman, President, and Chief Medical Officer
Lee Schwartzberg, MD, FACP, serves as President and Chief Medical Officer for Vector Oncology. He directs all clinical research initiatives, provides leadership, clinical oversight and management for Vector Oncology and its services. He continues his work as a medical oncologist and hematologist, senior partner and medical director in an ever-growing community-based private practice at The West Cancer Center. Dr. Schwartzberg is founding Editor-in-Chief for Oncologystat.com and was the founding Editor-in-Chief for Community Oncology Journal. He serves as the Division Chief of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center. Dr. Schwartzberg also serves on the Board of Directors for the National Comprehensive Cancer Network. His research interests include breast cancer, supportive care and developmental therapeutics, having published over 110 peer-reviewed publications.
After attending medical school at New York Medical College, he completed his residency and fellowship at Cornell University and Memorial Sloan-Kettering Cancer Center. He has been the recipient of numerous honors/awards for his work in the field of oncology, most recently, Castle Connelly Top Doctors and the Memphis Business Journal, Health Care Hero for Health Care Innovations.
Michael Choukas, Chief Executive Officer
Michael Choukas was appointed CEO of Vector Oncology in January, 2014, and has worked with the company as a strategic advisor since May, 2012. Prior to joining Vector Oncology, he served as Partner of private equity firm The Watermill Group. Previously, Mike served as President and CEO of Oncopartners, a Latin American oncology development services company, which he founded in 2006. Prior to his work with Oncopartners, he was a member of the leadership team of United Biosource Corporation (UBC) where he served as Executive Vice President of Strategy and Operations and Executive Chairman of the Late Stage Group from 2004 to 2006. In 1996, Mike founded Scirex Corporation and served as Scirex Chairman and CEO until 2003. He held senior leadership positions as Chairman and CEO of Springborn Laboratories, Executive Vice President of Dun and Bradstreet Software and Services, and as a Partner at Bain & Company, where he contributed to the leadership of Bain’s software and M&A practice areas. Mike began his career serving on the staff of the US Senate Committee on Environment and Public Works and then as Legislative Director for US Senator Patrick Leahy.
Mike currently serves as Chairman of the Board of Trustees for Vermont Academy, and as a Director of Tubes Holdco Ltd, a Watermill portfolio company. He has been a member of the Alumni Council of Dartmouth College. He holds an MBA from Harvard University and a BA in Economics from Dartmouth College.
Edward Stepanski, PhD, Chief Operating Officer
Edward Stepanski, PhD, joined Vector Oncology in 2006 after holding many leadership positions in academic medical centers and in national medical societies for over 20 years. Ed brings strong organizational expertise, scientific acumen at the highest academic standards, as well as sensitivity to the needs of oncology from both the business and clinical perspective. Under his leadership, Vector Oncology developed the Health Outcomes and PharmacoEconomics (HOPE) and Pharma Services business units. Ed has co-authored over 100 peer-reviewed papers, book chapters, and books covering many topics in oncology research, sleep medicine, and statistical methodology.
Sean Hart is the Executive Vice President and Managing Director of Vector Oncology overseeing the Global Pharma Services team including early phase and observational research.
Prior to joining Vector Oncology, Hart was the President of HPS, Pharma Consulting a business focused in oncology pharmaceutical services in early phase drug development.
From 2004 to 2013 Hart held many roles at United BioSource Corporation (UBC) with his most recent position being General Manager of Product Approval and Commercialization for UBC, a global medical and scientific affairs organization that partners with life science companies to develop and commercialize their products.
In this role, Sean provided strategic direction and operational oversight for six major business areas: Peri- and Post-approval Research, Pharmacovigilance, Outcomes Research, Health Economics, Clinical Operations Support, and Regulatory Affairs. He lead a global team of scientists, health researchers, and operational support professionals to provide comprehensive scientific and strategic solutions to support client needs for real-world data in product development and commercialization.
Sean was also a member of UBC’s Executive Leadership Team, with responsibilities including merger and acquisition support, and global operations management. He led UBC’s efforts to establish operations spanning Europe, including in Germany, Hungary, Switzerland, Spain and the United Kingdom, and continues to play a leading role in the company’s European expansion efforts. He was also the senior Governance executive for UBC’s many preferred provider relationships with pharmaceutical companies.
Prior to joining UBC, Sean was Chief Executive Officer of BBCI, a clinical research organization that specialized in Phase IV programs, and was acquired by UBC in 2004. During his tenure, BBCI achieved more than 30% growth annually.
Sean is a recognized industry leader in Phase IV clinical trials, post-marketing surveillance programs, and patient registries. His experience spans all major therapeutic areas and all phases of research and development.
Anne (Stratemeier) Werr, Executive Director, Finance
Anne has held executive level financial positions in the professional services industry, beginning her career at Arthur Andersen, LLP. She has worked with high growth businesses focusing on process improvement to control costs. She has also worked to integrate separate accounting teams into one cohesive team and has built an international accounting team. She has a Bachelor’s of Business Administration with a degree in Accounting from Texas Christian University. She is a CPA with licensure from the states of Kansas and Missouri.